Tricyclic inhibitors of poly(ADP-ribose)polymerase

A method for the treatment of a condition which can be ameliorated by inhibition of PARP in an individual in need thereof, the method comprising administering to the individual an effective amount of a compound of formula (I):

• wherein
• RA and RB are taken together with the carbon atoms to which they are attached to form a substituted or unsubstituted 6-membered aromatic ring, wherein the substituted 6-membered aromatic ring is substituted by RF, wherein RF is hydrogen, halo, —CF3, unsubstituted C1-C3 alkyl or unsubstituted C1-C3 alkoxy;
• each R1 and R2 is independently hydrogen, halo, hydroxy, unsubstituted C1-C3 alkyl or unsubstituted C1-C3 alkoxy;
• Z is a 6-membered aryl substituted with RC and RP;
• RC is hydrogen, halo, —CF3, unsubstituted C1-C3 alkyl or unsubstituted C1-C3 alkoxy;
• RP is a moiety of the formula (Ia) or (Ib):
• each X is independently O, S or absent;
• RD is hydrogen, substituted or unsubstituted alkyl, unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, —C(O)R4, —C(═N—CN)NR8R9 or —C(O)NR5R6;
• R4 is an unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted alkoxy, or substituted or unsubstituted heterocyclyl;
• each R5 and R6 is independently hydrogen, unsubstituted alkyl or unsubstituted cycloalkyl;
• each R8 and R9 is independently hydrogen, unsubstituted alkyl or unsubstituted cycloalkyl, or R8 and R9 are taken together with the nitrogen to which they are attached to form an unsubstituted heterocyclyl;
• RE is unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted aryl, or —OR7;
• and
• R7 is an unsubstituted alkyl or unsubstituted cycloalkyl;
• wherein the substituted alkyl, the substituted aryl, the substituted heteroaryl, and the substituted heterocyclyl are independently substituted by one, two, three, or more substituents, wherein the substituents are independently cyano, halo, haloalkyl, alkyl, alkylcarbonyl, cycloalkyl, or aryl;
• wherein said alkyl substituents are optionally substituted with hydroxyl,
• or a pharmaceutically acceptable salt or solvate thereof,
• wherein the condition is cancer selected from the group consisting of a breast cancer, an ovarian cancer and a cervical cancer.